Orthopaedic and dental abnormalities in osteogenesis imperfecta: A review of the literature

Journal of Biological Regulators and Homeostatic Agents

Volumn 25, Issue 3, 2011, Pages 313-321

  Scaramuzzo, L ^a   Raffaelli, L ^a   Spinelli, M S ^a   Damis, G ^a   Maccauro, G ^a   Manicone, P F ^a  

^a CATHOLIC UNIVERSITY   (Italy)

Author keywords

Bone fracture; Dentinogenesis imperfecta; Osteogenesis imperfecta

Indexed keywords

BISPHOSPHONIC ACID DERIVATIVE; COLLAGEN TYPE 1;

BONE FRAGILITY; BONE TURNOVER; CALLUS; CLINICAL FEATURE; COLLAGEN DEFECT; DENTIN; FRACTURE; GENE MUTATION; GROWTH RATE; HISTOPATHOLOGY; HUMAN; JOINT LAXITY; MALOCCLUSION; MOBILIZATION; OSTEOCLAST; OSTEOGENESIS IMPERFECTA; OSTEOLYSIS; OSTEOTOMY; PROGNOSIS; REVIEW; TOOTH MALFORMATION;

BONE RESORPTION; BONES OF LOWER EXTREMITY; BONY CALLUS; CHILD; CHILD, PRESCHOOL; COLLAGEN; DENTIN; FRACTURES, BONE; HUMANS; MUTATION; OSTEOGENESIS IMPERFECTA; TOOTH ABNORMALITIES;

EID: 80755142800     PISSN: 0393974X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (63)

1. Petersen K, Wetzel WE. Recent findings in classification of osteogenesis imperfecta by means of existing dental symptoms. J Dent Child 1998; 65:305-309. (Pubitemid 128686311)
2. Rios D, Vieira Falavihna AL, Tenuta Andlò LM, et al. Osteogenesis imperfecta and dentinogenesis imperfecta: Associated disorders. Quintessence Int 2005; 36:695-701. (Pubitemid 41242085)
3. Modesto A, Alves AC Vieira AR, et al. Dentinogenesis imperfecta type II: Case report. Braz Dent J 1996; 42:42-52.
4. Witkop CJ. Clincal aspects of dental anomalies. Int Dent J 1976;26:378-90.
5. Roughley PJ, Rauch F, Glorieux FH. Osteogenesis imperfecta: clinical and molecular diversity. Eur Cell Mater 2003; 5:41-47. (Pubitemid 38957400)
6. Schwartz S, Tspipouras P. Oral findings in osteogenesis imperfecta. Oral Surg Oral Med Oral Pathol 1984; 57:161-67.
7. McKuisick VA. Heritable disorders of connective tissue. J Chronic Dis 1956; 3:180-202.
8. Martin E, Shapiro JR. Osteogenesis imperfecta: epidemiology and pathophysiology. Curr Osteop Rep 2007; 5:91-97. (Pubitemid 47571959)
9. Rauch F, Glorieux FH. Osteogenesis imperfecta. Lancet 2004; 363:1377-85. (Pubitemid 38529880)
10. Seikaly MG, Kopanati S, Salhab N, et al. Impact of alendronate on quality of life in children with osteogenesis imperfecta. J Pediatr Orthop 2005; 25:786-91. (Pubitemid 41546416)
11. Morton ME. Excessive bleeding after surgery in osteogenesis imperfecta. Br J Oral Maxillofac Surg 2000; 38:399-400.
12. Abdelmalek NF, Gerber TL, Menter A. Cardiocutaneous syndromes and associations. J Am Acad Dermatol 2002; 46:161-83. (Pubitemid 34118371)
13. O'Connell AC, Marini JC. Evaluation of oral problems in an osteogenesis imperfecta population. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1999; 87:189-96.
14. Sillence DO, Senn A, Danks DM. Genetic heterogeneity in osteogenesis imperfecta. J Med Genet 1979; 16:101-16. (Pubitemid 9164903)
15. Lindau BM, Dietz W, Hoyer I, et al. Morphology of dental enamel and dentin-enamel junction in osteogenesis imperfecta. Int J Paediat Dent 1999; 9:13-21.
16. Maccauro G, Cittadini A, Magnani G, et al. In vivo characterization of zirconia toughened alumina material: a comparative animal study. Int J Immunopathol Pharmacol 2010; 23:841-46.
17. Sadeghi Koupaei MT, Ahangari G, Samanguiei Sh. Inflammatory mediator serotonin receptor gene (5-HTR3A) expression changes on human peripheral blood lymphocytes in rheumatoid arthritis. Eur J Inflamm 2010; 8:83-88.
18. Schierano G, Pejrone G, Roana J, et al. A split-mouth study on microbiological profile in clinical healthy teeth and implants related to key inflammatory mediators. Int J Immunopathol Pharmacol 2010; 23:279-88.
19. Lygidakis NA, Smith R, Oulis CJ. Scanning electron microscopy of teeth in osteogenesis imperfecta type I. Oral Surg Oral Med Oral Pathol Oral Radiol Endod 1996; 81:567-72. (Pubitemid 126808129)
20. Primorae D, Rowe DW, Mottes M, et al. Osteogenesis imperfecta at the beginning of bone and joint decade. Croatian Med J 2001; 42:393-415. (Pubitemid 32781446)
21. Amanti A, Potalivo G, Pelosi F, Rende R, Cerulli G. Randomized prospective study on the use of Eufiss in the prevention of infections in patients treated with external fixation. Eur J Inflamm 2010; 8:189-92.
22. Contasta I, Totaro R, Berghella A-M, Pellegrini P, Del Beato T, Carolei A, Adorno D. Soluble CD30: a biomarker for evaluating the clinical risk versus benefit of IFNß1a treatment in multiple sclerosis patients. Int J Immunopathol Pharmacol 2010; 23:213-26.
23. Shekhawat N, Vijayvergia R. Investigation of anti-inflammatory, analgesic and antipyretic properties of Madhuca indica Gmel. Eur J Inflamm 2010; 8:165-71.
24. Falvo K, Root L, Bullough P. Osteogenesis imperfecta: clinical evaluation and management. J Bone Joint Surg 1974; 56-A(4).
25. Major CC, Borggren CL, DeVries RM. Traumatic hand fracture in a patient with osteogenesis imperfecta. J Chirop Med 2008; 7:155-60.
26. Freemont AJ. The pathology of osteogenesis imperfecta. J Clin Pathol 1996; 49:618-19.
27. Vetter U, Ponta B, Zauner E, et al. Osteogenesis imperfecta: a clinical study of the first ten years of life. Calcif Tissue Int 1992; 50:36-41.
28. Migliore A, Padalino C, Massafra U, et al. Intra-articular injections of infliximab in the treatment of inflammatory rheumatic diseases: case reports and review of literature. Eur J Inflamm 2010; 8:49-54.
29. Neri G, Citraro L, Martinotti S, Toniato E, Castriotta A, De Rosa M, Filograna Pignatelli G. The role of atypical microorganisms in chronic oropharyngeal phlogosis. Eur J Inflamm 2010; 8:201-10.
30. Quaranta A, Ronconi LF, Di Carlo F, Vozza I, Quaranta M. Electrochemical behaviour of titanium in ammine and stannous fluoride and chlorexidine 0.2% mouthwashes. Int J Immunopathol Pharmacol 2010; 23:335-43.
31. Graham ES, Angel CE, Schwarcz LE, Dunbar PR, Glass M. Detailed characterisation of CB2 receptor protein expression in peripheral blood immune cells from healthy human volunteers using flow cytometry. Int J Immunopathol Pharmacol 2010; 23:25-34.
32. Scaramuzzo L, Messuti L, Manicone PF, et al. Clinical and histological modification in osteopetrotic bone a review. J Biol Regul Homeost Agents 2009; 23:59-63.
33. Monti E, Mottes M, Franchini P, et al. Current and emerging treatments for the management of osteogenesis imperfecta. Ther Clin Risk Manag 2010:6; 367-81.
34. Pietropaoli D, Tatone C, D'Alessandro AM, Monaco A. Possible involvement of advanced glycation end products in periodontal diseases. Int J Immunopathol Pharmacol 2010; 23:683-91.
35. Gargan MF, Wisbeach A, Fixsen JA. Humeral roding in osteognesis imperfecta. J Pediatr Orthop 1996; 16:719-22.
36. Antoniazzi F, Mottes M, Fraschini P, et al. Osteogenesis imperfecta: practical treatment guidelines. Pediatr Drugs 2000; 2:465-88.
37. Wolf H, Sarahrudi K, Vecsei V. Intramedullary osteosynthesis for fracture associated with osteogenesis imperfecta. Injury 2009; 40:315-20.
38. Zionts LE, Ebramzadeh E, Stott NS. Complications in the use of the Baley-Dabow extensible nail. Clin Orthop 1998; 348:186-95. (Pubitemid 28160823)
39. Chen Y-Z, Liu G, Senju S, et al. Identification of SARS-CoV spike protein-derived and HLA-A2-restricted human CTL epitope by using a new muramyl dipeptide-derivative adjuvant. Int J Immunopathol Pharmacol 2010; 23:165-77.
40. Mori F, Bianchi L, Pucci N, Azzari C, de Martino M, Novembre E. CD4+CD25+Foxp3+ T regulatory cells are not involved in oral desensitization. Int J Immunopathol Pharmacol 2010; 23:359-61.
41. Bocchino M, Matarese A, Bellofiore B, Giacomelli P, Russo A, Signoriello G, Galati D, Sanduzzi A. Usefulness of IFN-gamma release assays in clinical management of difficult TB cases: evidence from clinical practice. Eur J Inflamm 2010; 8:43-47.
42. McHale KA, Tenuta JJ, Tosi LL, McKay DW. Percutaneous intramedullary fixation of long bone deformity in severe osteogenesis imperfecta. Clin Orthop 1994; 305:242-48. (Pubitemid 24321003)
43. Munns CF, Rauch F, Travers R, Glorieux FH. Effects of intravenous Pamidronate treatment in infants with osteogenesis imperfecta: clinical and histomorphometric outcome. J Bone Miner Res 2005; 20:1235-43. (Pubitemid 40863813)
44. Gasparini G, Saponaro G, Di Nardo F, Moro A, Boniello R, Cervelli D, Marianetti TM, Palazzoni G, Pelo S. Clinical experience with spiramycin in bisphosphonate-associated osteonecrosis of the jaw. Int J Immunopathol Pharmacol 2010; 23:619-27.
45. Colella G, Cannavale R, Vicidomini A, Rinaldi G, Compilato D, Campisi G. Efficacy of a spray compound containing a pool of collagen precursor synthetic aminoacids (L-proline, L-leucine, L-lysine and glycine) combined with sodium hyaluronate to manage chemo/radiotherapy-induced oral mucositis: preliminary data of an open clinical trial. Int J Immunopathol Pharmacol 2010; 23:143-51.
46. Russell RG. Bisphosphonate mode of action and pharmacology. Pediatrics 2007; 119:S150-62.
47. Richardson VJ. Divergent and synergistic regulation of matrix metalloprotease production by cytokines in combination with C-C chemokines. Int J Immunopathol Pharmacol 2010; 23:715-26.
48. Vanderlocht J, van Elssen CHMJ, Senden-Gijsbers BLMG, Meek B, Cloosen S, Libon C, Bos GMJ, Germeraad WTV. Increased tumor-specific CD8+ T cell induction by dendritic cells matured with a clinical grade TLR-agonist in combination with IFN-γ. Int J Immunopathol Pharmacol 2010; 23:35-50.
49. Plotkin H, Rauch F, Bishop NJ, et al. Pamidronate treatment of severe osteogenesis imperfecta in children under 3 years of age. J Clin Endocrinol Metab 2000; 85:1846-50. (Pubitemid 32269287)
50. Rauch F, Travers R, Glorieux FH. Pamidronate in children with osteogenesis imperfecta: histomorphometric effects of long-term therapy. J Clin Endorinol Metab 2006; 91:511-16. (Pubitemid 43236917)
51. Ernst M, Rodan GA. Increased activity of insulin-like growth factor (IGF) in osteoblastic cells in the presence of growth hormone(GH): positive correlation with the presence of the GH-induced IGF binding protein BP3. Endocrinology 1990; 127:807-14. (Pubitemid 20248126)
52. Calabrò P, Riegler L, Limongelli G, et al. Production of serum amyloid A in response to inflammatory cytokines by human adipocytes. Eur J Inflamm 2010; 8:99-105.
53. Meng X, Tancharoen S, Kawahara K-I, Nawa Y, Taniguchi S, Hashiguchi T, Maruyama I. 1,5-anhydroglucitol attenuates cytokine release and protects mice with type 2 diabetes from inflammatory reactions. Int J Immunopathol Pharmacol 2010; 23:105-19.
54. Sillence B, Briody J, Adult J, et al. Factors which influence the efficacy of growth hormone in 15 children with osteogenesis imperfecta types I and IV. Sixth International Conference on Osteogenesis Imperfecta; 1996 Sep 19-21; Utrecht, The Netherlands.
55. Prockop DJ, Kivirikko KI. Collagens: molecular biology, diseases, and potentials for therapy. Ann Rev Biochem 1995; 64:403-34.
56. Capria A, De Nardo D, Baffetti FR, Barbini U, Violo A, Tondo T, Fontana L. Long-term anti-TNF-α treatments reverse the endothelial dysfunction in rheumatoid arthritis: the biological coherence between synovial and endothelial inflammation. Int J Immunopathol Pharmacol 2010; 23:255-62.
57. Galliera E, Locati M, Mantovani A, Corsi MM. Chemokine system: new inflammatory markers on the horizon. Eur J Inflamm 2010; 8:1-6.
58. Grassi G, Forlino A, Marini JC. Cleavage of collagen RNA transcripts by hammerhead ribozymes in vitro is mutation specific and shows competitive binding effects. Nucleic Acids Res 1997; 25:3451-58. (Pubitemid 27359220)
59. Millington-Ward S, McMahon HP, Allen D, et al. RNAi of COLIA1 in mesenchymal progenitor cells. Eur J Hum Genet 2004; 12:864-66. (Pubitemid 39406072)
60. Hossein-Nezhad A, Khoshniat Nikoo M, Mirzaei K, Mokhtarei F, Aghaei Meybodi HR. Comparison of the bone turn-over markers in patients with multiple sclerosis and healthy control subjects. Eur J Inflamm 2010; 8:67-73.
61. Zappacosta R, Caraceni D, Ciccocioppo L, Ottaviantonio M, Conti F, Andreozzi S, Petrucci F, Rosini S. Is HPV -DNA testing a useful tool in predicting low-grade squamous intraepithelial lesion outcome? A retrospective longitudinal study. Int J Immunopathol Pharmacol 2010; 23:317-26.
62. Sirotkin AV, Chrenek P, Pivko J, Balazi A, Makarevich AV Phosphodiesterase inhibitor 3-isobutyl-1-methyl-xanthine affects ovarian morphology and stimulates reproduction in rabbits. Eur J Inflamm 2010; 8:173-79.
63. Horwitz EM, Prockop DJ, Gordon PL, et al. Clinical responses to bone marrow transplantation in children with severe osteogenesis imperfecta. Blood 2001; 97:1227-31. (Pubitemid 32183743)